1,721,673 research outputs found
[[alternative]]The Investigation on the ＂Wu-ling-san Syndrome＂ in 《Shan-han-za-bing-lun》
No full text[[abstract]] 本研究之題目為《傷寒雜病論》中五苓散證之探討，其主要目的在討論《傷寒雜病論》中「五苓散證」的病因病機。 「五苓散」在《傷寒雜病論》中是一個很特殊的方劑，無論是從方名、組成、製服法到其適應證，在整個傷寒體系中都是極為獨特。再者，今日學術界對於「五苓散證」的解析，實有矛盾、不合理之處，對於此一現象，在論中有詳細探討，並期待找出一個最適切的理論來重新詮釋「五苓散證」。論中將對歷代醫家「五苓散證」的解釋作一探討；運用文字訓詁的考證，利用古代相關典籍；並配合其他醫學典籍與《傷寒論》相關的條文，對「五苓散」的組成、製服法作一全面的檢視。最後將各種《傷寒論》版本中「五苓散」相關條文作一整理比較，推敲出較適當的條文。 主流說法「太陽膀胱蓄水」或「膀胱蓄水」之觀點似是而非，無法滿足臨床上運用五苓散之時機。筆者運用上述方法，發現五苓散之病機應該是脾胃停飲，脾胃無法運化水濕，致三焦氣機不利，上則口渴，下則小便不利。提出對五苓散證全新的看法，說明五苓散證不能從太陽經脈、膀胱腑病的角度來加以詮釋，而應是中焦脾胃水氣之運化失調，所產生的病證。以期能更明確了解當初仲景製方之意，及「五苓散證」真正的病因病機，讓臨床上更能準確掌握運用的時機。[[abstract]] This article is to investigate the Wu-ling-san syndrome in 《Shan-han-za-bing-lun》. The main purpose is to discuss the real pathogensis of Wu-ling-san syndrome. Wu-ling-san syndrome is not a dangerous disease, but most people often neglect its real pathogenesis. The major viewpoint “stagnated fluid in bladder” is not totally matching in clinical treatment. The author using Zhongjing articles, ancient Chinese medicine canons, scholiastic classics and other Chinese medicine writtings to find out that the mechanism of Wu-ling-san syndrome is associated with spleen and stomach, where the dampness can’t be dispelled due to the dysfunction of stomach and spleen. It is also due to the inhibition of the qi circulating in sanjiao, so that occurs getting thirst and dysuria. Bring up a whole new explanation of pathogenesis on Wu-ling-san syndrome, and point out that Wu-ling-san syndrome can not be described from Urinary Bladder Meridian of Taiyang but the disorder of the spleen and stomach in middle jiao. Understanding the real mechanism of Wu-ling-san syndrome is stagnated fluid in stomach and spleen that can make us realizing the well application time for clinical treatment precisely
The Value of Combining Wu Ling San Plus and Minus with Repaglinide in the Treatment of Obese Type 2 Diabetes
Full text linkObjective: To investigate the clinical value and practical effects of the treatment of obese type 2 diabetes mellitus patients with Wu Ling San plus and minus combined with Repaglinide. Methods: Twenty-two obese type 2 diabetic patients attending the outpatient clinic of Yixing Traditional Chinese Medicine Hospital from September 2020 to March 2022 were randomly selected as the subjects of this study, and all of them were divided into treatment group (n=11, Wu Ling San plus and minus + Repaglinide) and control group (n=11, single Repaglinide) according to the computerized random series grouping method. The clinical data and overall efficacy of the two groups were compared. Results: After treatment, the treatment group had better blood glucose, blood lipids and other basic indicators than the control group (P<0.05); all Chinese medicine symptoms scores and complication rates of the treatment group were lower than those of the control group (P<0.05). Conclusion: The treatment of obese type 2 diabetes mellitus patients with Wu Ling San plus reduction + Repaglinide has significant efficacy and high drug safety, and can stabilize many indicators of blood glucose and blood lipids, reduce the risk of complications and control their body weight, which can be promoted and used in the treatment of related clinical conditions
CUHK electronic theses & dissertations collection
No full textWu Ling."Dec 2004."Thesis (Ph.D.)--Chinese University of Hong Kong, 2004.Includes bibliographical references.Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web.Mode of access: World Wide Web.Abstracts in English and Chinese
Perspective taking representation of bilateral negotiation: Total ignorance or partial ignorance of the other’s perspective
No full textFIGURES 1–2 in A new species of the genus Comidoblemmus Storozhenko & Paik (Orthoptera: Gryllidae) from Xizang, China
No full textFIGURES 1–2. Comidoblemmus yigongensis sp. nov. 1. male; 2. female. Scale bars: 1.0 mm.Published as part of Wu, Ling & Liu, Hao-Yu, 2017, A new species of the genus Comidoblemmus Storozhenko & Paik (Orthoptera: Gryllidae) from Xizang, China, pp. 137-140 in Zootaxa 4294 (1) on page 138, DOI: 10.11646/zootaxa.4294.1.10, http://zenodo.org/record/83157
FIGURES 7–9 in A new species of the genus Comidoblemmus Storozhenko & Paik (Orthoptera: Gryllidae) from Xizang, China
No full textFIGURES 7–9. Comidoblemmus yigongensis sp. nov. Male genitalia: 7 dorsal view; 8 ventral view; 9 lateral view.Published as part of Wu, Ling & Liu, Hao-Yu, 2017, A new species of the genus Comidoblemmus Storozhenko & Paik (Orthoptera: Gryllidae) from Xizang, China, pp. 137-140 in Zootaxa 4294 (1) on page 140, DOI: 10.11646/zootaxa.4294.1.10, http://zenodo.org/record/83157
A new species of the genus Comidoblemmus Storozhenko & Paik (Orthoptera: Gryllidae) from Xizang, China
No full textWu, Ling, Liu, Hao-Yu (2017): A new species of the genus Comidoblemmus Storozhenko & Paik (Orthoptera: Gryllidae) from Xizang, China. Zootaxa 4294 (1): 137-140, DOI: https://doi.org/10.11646/zootaxa.4294.1.1
FIGURES 3–6 in A new species of the genus Comidoblemmus Storozhenko & Paik (Orthoptera: Gryllidae) from Xizang, China
No full textFIGURES 3–6. Comidoblemmus yigongensis sp. nov. 3, 4. Head, frontal view; 5, 6. Supra anal plate, dorsal view. 3, 5. Male; 4, 6. Female. Scale bars: 1.0 mmPublished as part of Wu, Ling & Liu, Hao-Yu, 2017, A new species of the genus Comidoblemmus Storozhenko & Paik (Orthoptera: Gryllidae) from Xizang, China, pp. 137-140 in Zootaxa 4294 (1) on page 139, DOI: 10.11646/zootaxa.4294.1.10, http://zenodo.org/record/83157
Wu-Ling-San formula prophylaxis against recurrent calcium oxalate nephrolithiasis- a prospective randomized controlled trial
Full text linkWu-Ling-San (WLS) formula has been proved to prevent calcium oxalate nephrolithiasis both in vitro and in vivo. This is the first prospective, randomized and placebo-controlled clinical trial of WLS in calcium oxalate nephrolithiasis prevention. All patients who enrolled were asked to drink enough fluid to urinate at least 2 L daily during the study period. A 24-hour urine collection was performed to establish the baseline levels of multiple urinary parameters before taking the medicine. The patients were randomized and divided into two groups. The medication group took 2 gm WLS formula three times daily for 1 month. The control group took 2 gm placebo three times daily for 1 month. A 24-hour urine collection was performed to evaluate multiple urinary and serum parameters from all patients during the study period. A total of 39 patients were enrolled and 28 patients completed the study. Fourteen patients were allocated to WLS group and 14 patients to placebo group. After treatment, the mean urine output level increased to 2796.4 + 525.7 ml/day (percentage of change, 13.9 %) in the WLS formula group. With placebo therapy, the mean decreased slightly to 2521.4 + 762.7ml/day (percentage of change, -5.7 %). The percentage of change was significantly different between the two groups (independent t-test, P=0.02). No patient complained of side effects, such as fatigue, dizziness, musculoskeletal symptoms, or gastrointestinal disturbance. WLS formula is a promising adjunct to surgical and medical management of kidney stones. Active therapy with WLS formula has a positive effect on diuresis without leading to electrolyte imbalance.Key words: Calcium oxalate, Urinary Stone, Traditional Chinese Medicine, Wu-Ling-San Formula, Nephrolithiasis
- …
